Literature DB >> 15842954

Immunostimulatory sequences of DNA and conjugates in the treatment of allergic rhinitis.

David H Broide1.   

Abstract

Therapeutic strategies based on the use of immunostimulatory sequences of DNA containing a CpG motif (also known as ISS DNA, or CpG DNA) are focused on minimizing the allergenicity of immunotherapy while improving its effectiveness. Several ISS DNA-based methods of immunization (ISS DNA alone, ISS DNA conjugated to a protein allergen) have shown promise in animal models of asthma, and some of these ISS DNA-based therapies have entered clinical trials. These ongoing clinical trials will help to determine whether any of these ISS DNA-based therapies are safe and effective to use in subjects with allergic rhinitis and asthma.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15842954     DOI: 10.1007/s11882-005-0035-7

Source DB:  PubMed          Journal:  Curr Allergy Asthma Rep        ISSN: 1529-7322            Impact factor:   4.919


  20 in total

1.  Novel roles of CpG oligodeoxynucleotides as a leader for the sampling and presentation of CpG-tagged antigen by dendritic cells.

Authors:  H Shirota; K Sano; N Hirasawa; T Terui; K Ohuchi; T Hattori; K Shirato; G Tamura
Journal:  J Immunol       Date:  2001-07-01       Impact factor: 5.422

Review 2.  CpG motifs in bacterial DNA and their immune effects.

Authors:  Arthur M Krieg
Journal:  Annu Rev Immunol       Date:  2001-10-04       Impact factor: 28.527

3.  Immunostimulatory DNA sequences inhibit IL-5, eosinophilic inflammation, and airway hyperresponsiveness in mice.

Authors:  D Broide; J Schwarze; H Tighe; T Gifford; M D Nguyen; S Malek; J Van Uden; E Martin-Orozco; E W Gelfand; E Raz
Journal:  J Immunol       Date:  1998-12-15       Impact factor: 5.422

4.  CpG oligodeoxynucleotides do not require TH1 cytokines to prevent eosinophilic airway inflammation in a murine model of asthma.

Authors:  J N Kline; A M Krieg; T J Waldschmidt; Z K Ballas; V Jain; T R Businga
Journal:  J Allergy Clin Immunol       Date:  1999-12       Impact factor: 10.793

5.  Immunostimulatory DNA sequences inhibit respiratory syncytial viral load, airway inflammation, and mucus secretion.

Authors:  J Y Cho; M Miller; K J Baek; D Castaneda; J Nayar; M Roman; E Raz; D H Broide
Journal:  J Allergy Clin Immunol       Date:  2001-11       Impact factor: 10.793

6.  Oligodeoxynucleotides containing CpG motifs induce IL-12, IL-18 and IFN-gamma production in cells from allergic individuals and inhibit IgE synthesis in vitro.

Authors:  B Bohle; B Jahn-Schmid; D Maurer; D Kraft; C Ebner
Journal:  Eur J Immunol       Date:  1999-07       Impact factor: 5.532

7.  Conjugation of immunostimulatory DNA to the short ragweed allergen amb a 1 enhances its immunogenicity and reduces its allergenicity.

Authors:  H Tighe; K Takabayashi; D Schwartz; G Van Nest; S Tuck; J J Eiden; A Kagey-Sobotka; P S Creticos; L M Lichtenstein; H L Spiegelberg; E Raz
Journal:  J Allergy Clin Immunol       Date:  2000-07       Impact factor: 10.793

8.  Unique palindromic sequences in synthetic oligonucleotides are required to induce IFN [correction of INF] and augment IFN-mediated [correction of INF] natural killer activity.

Authors:  S Yamamoto; T Yamamoto; T Kataoka; E Kuramoto; O Yano; T Tokunaga
Journal:  J Immunol       Date:  1992-06-15       Impact factor: 5.422

9.  Amb a 1-immunostimulatory oligodeoxynucleotide conjugate immunotherapy decreases the nasal inflammatory response.

Authors:  Meri K Tulic; Pierre-Olivier Fiset; Pota Christodoulopoulos; Patrice Vaillancourt; Martin Desrosiers; François Lavigne; Joseph Eiden; Qutayba Hamid
Journal:  J Allergy Clin Immunol       Date:  2004-02       Impact factor: 10.793

10.  Immunostimulatory oligonucleotides attenuate airways remodeling in allergic monkeys.

Authors:  Michelle V Fanucchi; Edward S Schelegle; Gregory L Baker; Michael J Evans; Ruth J McDonald; Laurel J Gershwin; Eyal Raz; Dallas M Hyde; Charles G Plopper; Lisa A Miller
Journal:  Am J Respir Crit Care Med       Date:  2004-08-11       Impact factor: 21.405

View more
  1 in total

Review 1.  Toll or toll-free adjuvant path toward the optimal vaccine development.

Authors:  Ken J Ishii; Shizuo Akira
Journal:  J Clin Immunol       Date:  2007-03-17       Impact factor: 8.317

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.